A dose finding study of LY3884961 in patients with Gaucher disease

You likely can't join if

• 1. Clinically significant neurological signs and symptoms and/or behavioral disturbances. 2. Active and progressive bone disease expected to require surgical treatment in the next 6 months 3. History of total splenectomy or planned total splenectomy during the first 18 months of the study 4. Splenomegaly > 10 MN as evaluated by centrally read abdominal magnetic resonance imaging (MRI). 5. Evidence of clinically significant liver disease, fragile liver, or history of exposure to hepatotoxins 6. Thrombocytopenia with platelet count < 40 × 103 per μL 7. Severe hyperlipidemia (triglycerides > 1,000 mg/dL) 8. Current diagnosis of unstable or clinically significant cardiovascular conditions based on Investigator assessment 9. History of certain cancers within 5 years of Screening 10. Concomitant disease, condition or treatment which, in the opinion of the Investigator, would pose an unacceptable risk to the patient or interfere with the patient's ability to comply with study procedures or interfere with the conduct of the study. 11. Women, who are pregnant (i.e., positive serum or urine pregnancy result at Screening and or Check-in) or breastfeeding or intending to become pregnant during the course of the trial. 12. Use of any GD-related chaperone therapy within 4 weeks prior to Screening or expected need to initiate chaperone therapy during at least the first 18 months of the study 13. Any type of prior gene or cell therapy 14. Use of systemic immunosuppressant or steroid therapy other than protocol-specified immunosuppression 15. Participation in another therapeutic investigational drug or device study within 3 months or 5 half-lives of the study agent, whichever is longer (unless it can be documented that the patient received placebo) 16. Have an anti-AAV9 antibody titer of >1:40 as determined by the central laboratory. 17. Clinically significant abnormalities in laboratory test results at Screening 18.Have any contraindications for MRI, including claustrophobia or the presence of contraindicated metal (ferromagnetic) implants/cardiac pacemaker